About Biotav Shield

We are building a controllable oral live vaccine platform targeting respiratory pathogens, designed to block infection at its point of entry through scalable, needle-free delivery.

Our Vision:
To redefine global pandemic preparedness with accessible, high-efficacy vaccines.

Our Mission:
To develop next-generation vaccines that deliver both mucosal and systemic immunity, addressing key limitations of current approaches.

Market Opportunity
Despite widespread vaccination, major gaps remain:
Limited prevention of infection and transmission;
Rapid waning immunity requiring frequent boosters;
Injection-based delivery constraining scalability;
Cold-chain logistics limiting global reach.

These shortcomings leave a multi-billion-dollar global market underserved and the world vulnerable to future respiratory pandemics.

Technology Summary
Our platform enables oral delivery of live, controllable vaccines that induce immunity at mucosal surfaces while also generating systemic protection. This approach has the potential to improve efficacy, simplify distribution, and significantly expand global access.

 

A platform extensible beyond COVID-19

 

Potential Multi Valent Vaccine

 

Opportunity for early partnership or acquisition

Our Approach
Biotav Shield is developing a platform for orally delivered live attenuated vaccines, designed to activate immunity where infection begins.

  • Oral delivery via enteric capsule
  • Induction of mucosal (IgA) and systemic immunity
  • Designed for durable protection and transmission reduction